Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-29
2007-05-29
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S359000
Reexamination Certificate
active
10342965
ABSTRACT:
Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.
REFERENCES:
patent: 5691196 (1997-11-01), Mak et al.
patent: 5700650 (1997-12-01), Mak et al.
patent: 5721114 (1998-02-01), Abrahamsen et al.
patent: 5876968 (1999-03-01), Sirtori et al.
patent: 6258596 (2001-07-01), Benoit et al.
patent: 6367479 (2002-04-01), Williams
patent: 6391298 (2002-05-01), Radtke
patent: WO 96/37608 (1996-11-01), None
Bergeron et al. ‘Characterization of Human Apoliporotein A-I Expressed inEscherichia coli.’ Biochemica et Biophysica Acta. vol. 1344, pp. 139-152. 1997.
Aviram M et al., Paraoxonase Inhibits High-density Lipoprotein Oxidation and Preserves its Functions: A possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (8): 1581-1590 (1998).
Ayub A et al., Serum Paraoxonase after Myocardial Infarction. Arterioscler Thromb Vasc Biol. 1999; 19:330-335.
Bhalchandra J Kudchodkar et al., Dietary Fat Modulates Serum Paraoxonase 1 Activity in Rats. J. Nutr. 130:2427-2433 (2000).
Bielicki J and Oda M, Apolipoprotein A-IMilano and Apolipoprotein A-IParis Exhibit an Antioxidant Activity Distinct from That of Wild-Type Apolipoprotein A-I. Biochemistry 41:2089-2096 (Jan. 16, 2002).
Bruckert E et al., The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I Milano. Artherosclerosis 128 (1997) 121-128.
Frank E et al., Paraoxonase and its Role in Cardiovascular Disease. eJIFCC vol. 13, No. 2 at http://www.ifcc.org/ejifcc/vol13no2/1301200102.htm.
Graham A et al., Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis 135 (1997) 193-204.
James RW et al. Modulated serum activities and concentration of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis 139 (1998) 77-82.
Mackness B et al., Human Serum Paraoxonase. Gen. Pharmac. vol. 31, No. 3, pp. 329-336, 1998.
Oda M et al., Cysteine Substitutions in Apolipoprotein A-I Primary Structure Modulate Paraoxonase Activity. Biochemistry 40, 1710-1718 (Jan. 19, 2001).
Oda M et al.. Paraoxonase 1 Overexpression in Mice and its Effect on High-Density Lipoproteins. Biochem and Biophys Res Communications 290, 921-927 (2002).
Pruzanski W et al., Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res. 2000. 41:1035-1047.
Rodrigo L et al., Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. (2001) 354: 1-7.
Rosenblat M et al., Serum Paraoxonase Activity and the Extent of Lipid Peroxidation Are not Affected by Increased Levels of Human Apolipoprotein A-I: Studies in Transgenic Mice. Biochemistry 41:2089-2096 (Jan. 16, 2002).
Ryan R et al., Optimized bacterial expression of human apolipoprotein A-I. Protein Expression and Purification 27 (2003) 98-103.
Sirtori CR et al., Recombinant apolipoproteins for the treatment of vascular diseases Atherosclerosis 143 (1999) 29-40.
Tilly-Kiesi M et al., Subjects with ApoA-I(Lys107-->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII). Arterioscler Thromb Vasc Biol. May 1997;17(5):873-80.
Valabhji J et al., High-density lipoprotein composition and paraoxonase activity in Type 1 diabetes. Clinical Science (2001) 101, 659-670.
Forte Trudy M.
Oda Michael N.
Chew Wong Michelle
Gupta Anish
Lawrence Berkely National Laboratory
Santos Fernando
The Regents of the University of California
LandOfFree
Apolipoprotein A-I mutant proteins having cysteine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apolipoprotein A-I mutant proteins having cysteine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apolipoprotein A-I mutant proteins having cysteine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782288